XML 30 R16.htm IDEA: XBRL DOCUMENT v3.25.2
Stock Incentive Plans
 6 Months Ended
Jun. 30, 2025
Share-Based Payment Arrangement [Abstract]  
Stock Incentive Plans STOCK INCENTIVE PLANS
As of June 30, 2025, the Company had a total of 1,633,869 shares available for grant under its 2016 Inducement Equity Incentive Plan, 2019 Inducement Equity Incentive Plan, and 2024 Equity Incentive Plan.
Stock Options
The following table summarizes stock option activity during the six months ended June 30, 2025:
Number of Shares
Weighted-
Average
Exercise
Price
Stock options outstanding at December 31, 2024
3,409,912 $22.63 
Granted
— — 
Exercised
(241,611)16.87 
Forfeited
(78,191)24.36 
Expired
(334,398)41.76 
Stock options outstanding at June 30, 2025
2,755,712 20.67 
Stock options exercisable at June 30, 2025
1,873,207 $22.77 
Restricted Stock Units (“RSUs”) and Performance Restricted Stock Units (“PSUs”)
The following table summarizes RSUs and PSUs activity during the six months ended June 30, 2025:
Number of Shares
Weighted-
Average
Grant Date
Fair Value
RSUs and PSUs outstanding at December 31, 2024
4,842,670 $15.38 
RSUs granted
1,354,743 19.34 
RSUs vested
(1,289,812)15.39 
RSUs forfeited
(566,696)14.10 
PSUs granted
252,405 19.49 
PSUs vested
(250,863)15.14 
PSUs forfeited
(53,212)26.34 
RSUs and PSUs outstanding at June 30, 2025
4,289,235 $16.33 
The PSUs granted to employees include financial and operational vesting metrics to be met over a performance period of two years. The number of shares underlying outstanding and unvested PSUs was 304,815 and 335,583 as of June 30, 2025 and December 31, 2024, respectively.
2014 Employee Stock Purchase Plan
The Company has an Employee Stock Purchase Plan (the “ESPP”) under which employees can purchase shares of its common stock based on a percentage of their compensation, but not greater than 15% of their respective earnings, provided an eligible employee’s right to purchase shares of the Company’s common stock may not accrue at a rate which exceeds $25,000 of the fair market value of such shares for each calendar year in which such rights are outstanding. The ESPP has consecutive offering periods of approximately six months in length. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock on the first day of the offering period or on the exercise date.
During the offering period in 2025 that ended on June 30, 2025, 84,234 shares were purchased pursuant to the ESPP for aggregate proceeds of $1.4 million from the issuance of such shares, which occurred on June 30, 2025.
During the offering period in 2024 that ended on December 31, 2024, 66,747 shares were purchased pursuant to the ESPP for aggregate proceeds of $0.9 million from the issuance of such shares, which occurred on January 2, 2025. 
Stock-Based Compensation Expense
The following table summarizes stock-based compensation expense relating to employee and non-employee stock-based awards for the three and six months ended June 30, 2025 and 2024, included in the condensed consolidated statements of operations as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Cost of testing services$329 $357 $692 $814 
Cost of product108 225 339 542 
Cost of patient and digital solutions189 350 409 722 
Research and development1,407 1,628 2,766 3,388 
Sales and marketing2,146 2,927 4,730 5,971 
General and administrative5,245 10,912 9,419 21,535 
Total$9,424 $16,399 $18,355 $32,972 
As of June 30, 2025, unrecognized stock-based compensation expense related to stock options, RSUs, and PSUs was approximately $8.0 million, $42.4 million, and $2.9 million, respectively. The remaining unrecognized compensation cost related to the unvested stock options, RSUs, and PSUs is expected to be recognized over a weighted-average period of 2.52 years, 2.27 years, and 2.42 years, respectively.